Document Type
Article
Publication Date
10-14-2025
Identifier
DOI: 10.1182/bloodadvances.2025016824
Abstract
Hematotoxicity is the most frequent severe toxicity after chimeric antigen receptor T-cell (CAR-T) therapy. However, limited data exist on risk factors and outcomes for hematotoxicity for children and young adults (CAYAs) with B-acute lymphoblastic leukemia treated with tisagenlecleucel. We conducted a multi-institutional study involving 326 CAYAs, with 144 evaluable in an initial training cohort and 141 evaluable in a validation cohort, through the Pediatric Real-World CAR Consortium to characterize the incidence and outcomes of prolonged severe neutropenia (PSN) and to develop a predictive risk score for PSN, tailored for use in this population. The incidence of PSN, defined as an absolute neutrophil count of < 0.5 x 103 cells per μL for ≥30 days, was 15.3% in the initial training cohort and 21% in the validation cohort. Development of PSN was associated with inferior overall survival (P < .001), relapse-free survival (P = .01), higher nonrelapse mortality (P = .003), and a greater risk of infections within 30 days (P = .03). Multivariable penalized regression analysis identified key risk factors for PSN, which included preinfusion C-reactive protein and bone marrow disease burden, and postinfusion peak ferritin and occurrence of severe cytokine release syndrome, which were used to create the CytoRisk score. In the validation cohort, the CytoRisk score discriminated between patients with and without PSN (area under the curve, 0.90; specificity, 93%; sensitivity, 71%; positive predictive value, 74%; and negative predictive value, 92%). The CytoRisk score may be used to a priori identify patients at highest risk of PSN and overall worse outcomes.
Journal Title
Blood Adv
Volume
9
Issue
19
First Page
5070
Last Page
5084
MeSH Keywords
Humans; Child; Neutropenia; Male; Female; Adolescent; Child, Preschool; Receptors, Antigen, T-Cell; Risk Factors; Immunotherapy, Adoptive; Young Adult; Infant
PubMed ID
40690779
Keywords
Neutropenia; Antigen T-Cell Receptors; Risk Factors; Adoptive Immunotherapy
Recommended Citation
Naik S, Selukar S, Talleur AC, et al. Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. Blood Adv. 2025;9(19):5070-5084. doi:10.1182/bloodadvances.2025016824


Comments
Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution.
Publisher's Link: https://ashpublications.org/bloodadvances/article/9/19/5070/546295/Characterization-and-prediction-of-prolonged